Physician profile
Arthur Samia
NPI 1912571779
$3,343.62
in general payments reported to CMS, 2019-2025
11 companies · $263 in 2025
The $263 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $242 · 2023: $1,437 · 2024: $1,401 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,101.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $850.97 | 2023-2024 | Rinvoq, Skyrizi |
| Galderma Laboratories, L.P. | $482.29 | 2022-2024 | Aklief, Twyneo |
| Novartis Pharmaceuticals Corporation | $440.42 | 2024-2025 | |
| Amgen INC. | $358.73 | 2024 | Otezla |
| Ucb, INC. | $278.13 | 2023-2024 | Cimzia, Bimzelx |
| Almirall LLC | $252.47 | 2023-2024 | Klisyri |
| Regeneron Healthcare Solutions, INC. | $219.66 | 2022-2023 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $130.71 | 2023 | Sotyktu |
| Janssen Biotech, INC. | $128.90 | 2024 | Tremfya |
| Lilly USA, LLC | $109.29 | 2025 | Ebglyss |
| Krystal Biotech INC | $92.05 | 2023 | Vyjuvek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Samia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.